Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. (an Israeli biotechnology company) reports on the month of February 2004. The document primarily serves as a notice and proxy statement for the Annual General Meeting of Shareholders scheduled for June 1, 2004. The filing incorporates the discussion of audited financial statements for the fiscal year ended December 31, 2003, though the specific financial data is not included in this text.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the period ended December 31, 2003. The document states that audited financial statements for this period will be discussed at the meeting but does not reproduce the figures.
However, the following financial-related data points are disclosed regarding governance and compensation:
- Director Compensation (2003): Aggregate compensation paid to all directors was approximately US$340,939, including US$59,681 in accrued pension/severance benefits.
- Director Stock Options (2003): 500,000 options granted to the Board of Directors with exercise prices ranging from US$2.38 to US$5.91 per share.
- Auditor Fees: Audit fees for 2004 are set at US$60,000. Non-audit fees for 2003 were US$31,250.
- Outstanding Shares: As of April 23, 2004, there were 27,424,158 Ordinary Shares outstanding.
Material Changes and Proposals
The filing outlines several material proposals requiring shareholder approval:
- Executive Compensation Changes:
- Approval of a one-time cash bonus of US$40,000 to CEO Dr. Mor Amitai for 2003 performance.
- Approval of a salary increase for Dr. Mor Amitai to US$240,000 annually, effective January 1, 2004.
- Approval of a grant of 26,500 stock options to Director Dr. David Haselkorn at an exercise price of US$5.99 per share, vesting over 48 months.
- Corporate Governance:
- Election of six directors, including two outside directors (Dr. Orna Berry and Mr. David Schlachet) for a second three-year term.
- Amendment to the Articles of Association to delete Article 46, which currently allows directors to unilaterally nominate alternate directors.
- Auditor Ratification: Ratification of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as independent external auditors for 2004.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors regarding the company's business operations. The primary focus is on corporate governance compliance with the Israeli Companies Law, specifically regarding the election of outside directors and the ratification of director compensation.
Unusual Items: The filing notes specific voting thresholds required for the election of outside directors, which differ from standard majority votes to ensure non-controlling shareholder representation.
Investor Verification Checklist
- Verify the actual financial performance (revenue, net loss, cash position) for the year ended December 31, 2003, by reviewing the full audited financial statements referenced in the meeting agenda.
- Confirm the impact of the proposed salary increase and bonus on the company's cash burn rate and future liquidity.
- Review the dilution impact of the proposed 26,500 options to Dr. Haselkorn and the 500,000 options previously granted to the Board.
- Assess the implications of deleting Article 46 of the Articles of Association on board flexibility and succession planning.
- Check the current share price relative to the proposed option exercise price of US$5.99 to evaluate the incentive value for Dr. Haselkorn.